Newmont Corporation (NEM) stock rose approximately +19% over the past 30 days, driven primarily by a sharp recovery in gold prices to record highs near $5,000 per ounce. Over the past quarter, shares gained +2%, reflecting sustained gold market strength offset by rising operational costs and production disruptions.

AEM shares surged +23% over the past 30 days, propelled by a rally in gold prices amid geopolitical tensions and safe-haven demand. Over the past quarter, AEM gained +5%, reflecting volatility with a mid-period dip followed by recovery on strong operational results and higher gold realizations.

INFY rose approximately +10% over the past 30 days, driven by rallies in IT stocks, strategic AI partnerships, and positive trading in Asian ADRs. Over the past quarter, the ETF declined -21%, reflecting analyst downgrades, growth concerns, and broader IT sector pressures.

Shares of OPTX closed down approximately 17.01% on Friday, April 17, 2026, falling from a prior session close of $11.05 to approximately $9.17, extending the deep correction that accelerated following the company's late-March earnings release and cautious 2026 revenue outlook.

Shares of JLHL plunged approximately 34.16% on Friday, April 17, 2026, closing at approximately $6.40 versus a prior session close of $9.72, as speculative momentum collapsed following extraordinary recent price swings in the micro-cap stock.

Shares of LNZA collapsed approximately 37.13% on Friday, April 17, 2026, closing at approximately $22.57 versus the prior day's close of $35.90, in one of the most severe single-session selloffs for the stock on record.

Shares of OPTX are plunging approximately 16.74% in Friday's session, declining from a prior close of $11.05 to approximately $9.20, extending a sharp de-rating that began after the company's full-year 2025 results and 2026 guidance revealed consecutive quarters of expected revenue decline.

Shares of VET gapped down sharply at Friday's open, falling approximately 7% from a prior close of $12.46 to the vicinity of $11.59, as the U.S.-Iran ceasefire deal triggers a roughly 13% collapse in crude oil prices — the dominant force behind today's energy sector selloff.

OPTX stock rose +32% over the last 30 days, driven by new defense and space optics orders signaling strong demand. Over the past quarter, shares surged +146%, fueled by revenue growth, narrowed losses, and multiple contract wins in high-margin sectors.

Shares of IPI are falling approximately 9% in Friday's session, declining from a prior close of $39.22 to approximately $35.69, as the geopolitical fertilizer price premium that fueled the stock's sharp year-to-date rally rapidly deflates.

Shares of VG are falling approximately 9% in Friday's session, declining from a prior close of $12.68 to approximately $11.54, as the geopolitical LNG war premium that powered the stock's dramatic 2026 rally continues its rapid deflation.

Greenland Energy Company (GLND) shares are falling approximately 23% today, trading near $6.13 versus a prior close of approximately $7.96 — extending a catastrophic decline from the stock's all-time high of $23.00 hit just three weeks after its Nasdaq debut. The selloff reflects a continued post-SPAC merger unwind: GLND began trading on March 26, 2026, surged 57.96% on its first trading day, then immediately collapsed, and has lost more than 69% of its value since late March as speculative enthusiasm fades.

GLND has declined approximately -32% over the past 30 days amid high volatility following its recent listing on NASDAQ. Over the past quarter, the stock is down around -26%, reflecting post-listing hype fade and broader energy sector pressures.

Crescent Biopharma (CBIO) stock surged +75% over the last 30 days, driven by fresh analyst buy ratings and sustained momentum from clinical trial advancements. Over the past quarter, shares climbed +44%, fueled by the first patient dosing in the ASCEND trial and positive full-year earnings outlook highlighting cash runway into 2028.

VET declined approximately -12% over the past 30 days amid a broader energy sector pullback and softening oil prices following early April peaks. Over the past quarter, VET rose +28%, driven by strong Q1 2026 production beats, strategic asset acquisitions in Germany, and favorable European natural gas pricing.

Venture Global (VG) stock declined 23% over the last 30 days, driven by profit-taking after a March rally, analyst price target reductions, and technical sell signals. The stock rose 30% over the past quarter, fueled by surging LNG demand, new long-term contracts, and strong Q4 earnings.

IPI declined approximately 12% over the past 30 days, pulling back from mid-March highs amid profit-taking and softer commodity sentiment. Over the past quarter, the stock rose about 4%, buoyed by a strong Q4 earnings report and rising fertilizer demand.

CG Oncology's shares have shown strong upward momentum in recent weeks, driven by clinical progress and analyst enthusiasm. Topline data from the pivotal Phase 3 PIVOT-006 trial is slated for the first half of 2026, a key catalyst for potential approval.

Relay Therapeutics (RLAY) stock surged +62% over the past 30 days, driven by positive clinical data reveals on zovegalisib, including expansions into vascular anomalies and combination therapy updates. The stock climbed +112% over the past quarter, fueled by FDA Breakthrough Therapy designation for zovegalisib in breast cancer and narrowing losses in Q4 earnings.

Sustained higher interest rates could enhance net interest margins (NIM, a key profitability measure for banks) for major holdings, positioning FNCL for potential outperformance. Growth in capital markets activity and merger-and-acquisition (M&A) deals may boost investment banking revenues within the ETF's diversified financial exposures.